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AbstrAct
Chronic diarrhoea is a common problem, hence clear 
guidance on investigations is required. This is an 
updated guideline from 2003 for the investigations of 
chronic diarrhoea commissioned by the Clinical Services 
and Standards Committee of the British Society of 
Gastroenterology (BSG). This document has undergone 
significant revision in content through input by 13 
members of the Guideline Development Group (GDG) 
representing various institutions. The GRADE system was 
used to appraise the quality of evidence and grading of 
recommendations.
These guidelines deal with clinical assessment in 
primary and secondary care of a patient with diar-
rhoea, the exclusion of cancer or inflammation, and 
detecting common disorders such as bile acid diar-
rhoea, microscopic colitis, lactose malabsorption or 
post radiation diarrhoea, together with rarer causes 
of malabsorption and surgical disorders as outlined 
in figure 1. Options for therapy are not dealt with as 
it is beyond the remit of this guideline, nor has the 
cost effectiveness of investigations been addressed 
due to paucity of available evidence.
1 PrefAce
1.1 Purpose of guidelines
The guidelines are directed at consultant gastro-
enterologists, gastrointestinal surgeons, specialist 
registrars in training and general practitioners, and 
refer specifically to adult not paediatric gastroenter-
ology. Their purpose is to provide guidance on the 
best available methods of investigating symptoms of 
chronic diarrhoea. Given this broad symptom-based 
focus, the guidelines cover a wide range of gastro-
enterological conditions and are not intended as a 
comprehensive review of all aspects of the clinical 
conditions mentioned herein, but rather an attempt 
to rationalise the approach to investigation in the 
context of this common clinical scenario.
1.2 Development of guidelines and rigour
The guidelines were prepared following a compre-
hensive literature search by the guideline devel-
opment group (GDG). The GDG membership 
comprises elected members of the BSG, Association 
of Coloproctology of Great Britain and Ireland, 
Association of Biochemistry UK, British Institute 
of Radiology, Primary Care Society for Gastroen-
terology, and nurse and patient representatives. 
Each main section was authored by a designated 
member of the GDG following a comprehensive 
review of the literature including NICE, American 
and European guidelines. This involved a review of 
electronic databases (Medline and PubMed) using 
keywords (in both British and American spelling) 
such as ((((‘diarrhoea-predominant irritable bowel 
syndrome’ OR ‘chronic diarrhoea’ OR ‘functional 
diarrhoea’ OR ‘loose stools’ OR ‘faecal urgency’ OR 
‘faecal incontinence’ OR ‘stool frequency’) AND 
((diarrhoea[Title/Abstract]) AND (investigation 
OR investigate OR diagnostic OR diagnosis) AND 
"2000’(Publication Date): ‘3000’(Publication Date)) 
AND English(Language)) NOT case reports (Publi-
cation Type))). Additional terms related to the 
specific conditions mentioned in the text (eg, coeliac 
disease, bile acid diarrhoea or malabsorption and 
small bowel bacterial overgrowth). The time frame 
for literature review was from 2002 to April 2017. 
A total of 1292 key papers and relevant abstracts 
in English in peer-reviewed journals were identi-
fied and read, and relevant work has been cited and 
referenced. An initial draft document was produced 
and subsequently reviewed and modified in accor-
dance with the AGREE tool.1 Two face-to-face 
meetings as well as a further two telephone meet-
ings were held in preparing this guideline. We used 
a modified Delphi system to a maximum of three 
rounds for any contentious issues. A final decision 
was made once agreement was reached by 70% 
of the group. The lead author acted as facilitator. 
The review was undertaken through submission 
to members of the BSG Clinical Standards Service 
Committee as well as to BSG Council and finally 
international peer review.
1.3 Grading of recommendations
In accordance with the BSG advice on produc-
tion of guidelines, the GDG applied the GRADE 
system.2 Strength of recommendation was strong, 
moderate or weak. Where the recommendation 
was unanimous a ‘strong’ recommendation was 
used, and where the decision was by majority and 
the recommendation was moderate or weak, ‘we 
suggest’ was used. We graded the evidence based on 
levels 1–5 as per the Oxford Centre for Evidence 
Based Medicine.3 In brief, Level 1a–c ranges from 
systematic reviews with homogeneity, individual 
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randomised controlled trials (RCTs); Level 2a–c ranges from 
systematic reviews of cohort studies, low quality RCTs and 
outcomes research; Level 3a–b ranges from systematic reviews 
with heterogeneity and individual case control studies; Level 
4 are poor quality cohort or case series; and Level 5 is expert 
opinion without critical appraisal.
Specific RCTs addressing the investigation of ‘chronic diar-
rhoea’ are absent. Thus our grading of evidence was based on 
figure 1 Algorithm for the investigation of chronic diarrhoea based on clinical differential diagnosis.
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summary of all recommendations
We recommend the following investigation algorithm based on the clinical differential diagnosis outlined in figure 1.
clinical assessment
 ► We recommend a careful detailed history to plan investigations (Grade of evidence level 1, Strength of recommendation strong).
 ► We recommend screening blood tests for the exclusion of anaemia, coeliac disease, etc as well as stool tests for inflammation (Grade 
of evidence level 1, Strength of recommendation strong).
 ► We recommend making a positive diagnosis of irritable bowel syndrome (IBS) following basic blood and stool screening tests (Grade of 
evidence level 2, Strength of recommendation strong).
cancer or inflammation
 ► We recommend excluding colorectal cancer in those with altered bowel habit±rectal bleeding by colonoscopy (Grade of evidence level 
1, Strength of recommendation strong).
 ► We suggest use of testing for faecal blood loss by faecal immunochemical testing in primary or secondary care, either as an exclusion 
test or to guide priority of investigations in those with lower gastrointestinal symptoms (chronic diarrhoea) but without rectal bleeding 
(Grade of evidence level 2, Strength of recommendation weak).
 ► Faecal calprotectin is recommended to exclude colonic inflammation in those suspected with IBS and under the age of 40 (Grade of 
evidence level 1, Strength of recommendation strong).
secondary clinical assessment
 ► If symptoms persist despite normal first-line investigations and treatment, then referral for further investigations is recommended 
(Grade of evidence level 5, Strength of recommendation strong).
 ► We recommend blood and stool tests to exclude malabsorption and common infections (especially in the immunocompromised or 
elderly) (Grade of evidence level 2, Strength of recommendation strong).
common disorders
 ► In those with functional bowel or IBS-diarrhoea, a positive diagnosis of bile acid diarrhoea should be made either by75SeHCAT testing 
or serum bile acid precursor 7α-hydroxy-4-cholesten-3-one (depending on local availability) (Grade of evidence level 1, Strength of 
recommendation strong).
 ► There is insufficient evidence to recommend use of an empirical trial of treatment for bile acid diarrhoea rather than making a positive 
diagnosis (Grade of evidence level 5, Strength of recommendation strong).
 ► We recommend colonoscopy with biopsies of right and left colon (not rectal) to exclude microscopic colitis (Grade of evidence level 1, 
Strength of recommendation strong).
Malabsorption
 ► If lactose maldigestion is suspected, we suggest hydrogen breath testing (if available) or withdrawal of dietary lactose/
carbohydrates from the diet (Grade of evidence level 3, Strength of recommendation weak).
 ► MR enterography is recommended for evaluation of small bowel abnormalities depending on availability (Grade of evidence level 1, 
Strength of recommendation strong).
 ► Video capsule endoscopy (VCE) is recommended for assessing small bowel abnormalities depending on local availability (Grade of 
evidence level 1, Strength of recommendation strong).
 ► We do not recommend small bowel barium follow through or barium enteroclysis for the evaluation of small bowel abnormalities due 
to its poor sensitivity and specificity (Grade of evidence level 5, Strength of recommendation strong).
 ► We recommend enteroscopy only for targeted lesions identified by MR enterography or VCE and not for diagnosis of chronic diarrhoea 
(Grade of evidence level 4, Strength of recommendation strong).
 ► We recommend faecal elastase testing when fat malabsorption is suspected. We do not recommend PABA testing (Grade of evidence 
level 1, Strength of recommendation strong).
 ► MRI (rather than CT) is recommended for assessing structural anomalies of the pancreas in suspected chronic pancreatitis (Grade of 
evidence level 2, Strength of recommendation strong).
 ► If small bowel bacterial overgrowth is suspected, we recommend an empirical trial of antibiotics as there is insufficient evidence to 
recommend routine hydrogen or methane breath testing (Grade of evidence level 3, Strength of recommendation strong).
surgical and structural disorders
 ► We recommend use of anorectal manometry and endoanal ultrasound only when other local pathology has been excluded and 
conservative measures exhausted (Grade of evidence level 3, Strength of recommendation strong).
 ► We recommend radiological modalities for the investigation of fistulae—MRI or CT with contrast follow through (Grade of evidence 
level 3, Strength of recommendation strong).
rare causes
 ► Diarrhoea due to hormone secreting tumours is rare, hence we recommend testing only when other causes of diarrhoea have been 
excluded (Grade of evidence level 4, Strength of recommendation strong).
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the level of evidence (1–5) and the strength of our recommenda-
tion (strong, moderate or weak).
1.4 scheduled review of guidelines
These guidelines will be subject to future revisions within 5 years 
to take into account new developments and alternative investi-
gative methods.
1.5 Possible audit goals
The aim of these guidelines was to establish an optimal inves-
tigative scheme for patients presenting with chronic diarrhoea 
that would maximise a positive diagnosis while minimising the 
number and invasiveness of investigations. These two poten-
tially opposing directives are influenced by the potential seri-
ousness of the diagnostic outcome. Thus a low threshold for the 
use of colonoscopy is acceptable in the context of the frequency 
and clinical significance of colonic neoplasia in older subjects. 
However, there is less need for extensive investigation where the 
probability of benign disease is high (eg, in young patients with 
functional symptoms).4 Suggested goals for future audit include:
1. All patients undergoing colonoscopy for chronic diarrhoea 
should undergo biopsies of the right and left colon for 
histological examination.
2. Reduction of missed diagnoses of colorectal cancer to <1% 
through utility of faecal immunochemical testing (FIT) and 
endoscopic examination.
3. Minimising inappropriate first-line investigations (eg, colo-
noscopy) in patients less than 40 years of age without rectal 
bleeding and normal faecal calprotectin.
4. Initial non-invasive investigations, including coeliac serology, 
faecal calprotectin and possibly FIT, should be completed in 
primary care prior to specialist referral.
5. All patients with persistent undiagnosed chronic diarrhoea 
should be investigated for bile acid diarrhoea with SeHCAT 
or serum 7-alpha-hydroxy-4-cholesten-3-one or faecal bile 
acid measurement where available.
2 IntroDuctIon
2.1 Definition
Diarrhoea may be defined in terms of stool frequency, consis-
tency, volume or weight. Patients’ concept of diarrhoea often 
focuses around stool consistency.5 Indeed, faecal consistency is 
determined by the water-holding capacity of the stool (ie, the 
amount of non-bound ‘free’ water), and this perhaps best defines 
the concept of diarrhoea. However, quantification of this in clin-
ical practice may prove difficult, hence utility of the Bristol stool 
chart is recommended—type 5 and above (see online supple-
mentary material).6
In the past, stool weights were used (≥200 g/day), but this can 
be misleading as stool weights vary greatly and ‘normal’ stool 
volumes can exceed this value, particularly when non-Western 
diets are encountered. Hence stool weights are not recom-
mended as a measure of diarrhoea.
Further potential for confusion arises from the discrepancy 
between the medical and ‘lay’ concepts of diarrhoea, and this 
needs to be clarified at the initial appraisal. Faecal incontinence 
in particular is commonly misinterpreted as diarrhoea,7 while 
symptoms relating to functional bowel disease can be difficult to 
distinguish from organic pathology on the basis of history alone.
There is no consensus on the duration of symptoms that 
define chronic as opposed to acute diarrhoea. However, most 
groups including this GDG accept that symptoms persisting for 
longer than 4 weeks suggest a non-infectious aetiology and merit 
further investigation.8
A recent report suggests that both increased frequency and 
altered consistency is indicative of organic aetiology.9 Thus 
a pragmatic definition incorporates these elements: chronic 
diarrhoea is the persistent alteration from the norm with stool 
consistency between types 5 and 7 on the Bristol stool chart and 
increased frequency greater than 4 weeks' duration.
2.2 Prevalence
Chronic diarrhoea is one of the most common reasons for 
referral to a gastroenterology clinic. Prevalence rates in Western 
populations are difficult to estimate, partly through popula-
tion differences but also through difficulties in definition. In 
two population surveys, Talley et al reported a prevalence of 
‘chronic diarrhoea’ of between 7% and 14% in an elderly popu-
lation, a proportion of which is likely to include patients with 
motility disorders (ie, ‘functional bowel disease’). Using a defini-
tion based on excessive stool frequency without the presence of 
abdominal pain, estimates of the prevalence of chronic diarrhoea 
in a Western population are 4–5%.10
2.3 Difficulties in establishing guidelines for the investigation 
of chronic diarrhoea
Reported change in stool frequency or form is characteristic of 
irritable bowel syndrome (IBS) and indeed forms part of the defi-
nition of the condition, which relies on symptom-based criteria 
and negative physical examination.11 12Although stool weight 
does not usually increase in IBS, as symptom reporting forms the 
basis for the diagnosis and stool weight is rarely performed early 
in the course of investigation, considerable overlap between 
functional bowel disease and true ‘diarrhoea’ occurs. As IBS 
may affect 10–13% of the population,4 13 14 there is clearly the 
potential for inappropriate investigation of patients reporting 
diarrhoeal symptoms. Conversely, new onset of diarrhoea may 
reflect serious organic disease such as colonic neoplasia. It is this 
wide diagnostic potential given similar reported symptoms that 
makes the introduction of specific guidelines difficult.
The broad range of conditions which lead to diarrhoea also 
make it difficult to be too prescriptive with regard to the inves-
tigative pathways that should be adopted. Diarrhoea may result 
from: (a) colonic neoplasia; (b) inflammation; (c) small bowel 
inflammation; (d) small bowel malabsorption; (e) maldigestion 
due to pancreatic insufficiency; or (f) motility disorders, and it 
can be difficult to separate these on clinical grounds alone. The 
decision on whether to focus investigations on any one of these 
areas remains largely a matter of clinical judgement although, 
as will be discussed, the prevalence and potential seriousness 
of certain conditions (eg, colonic neoplasia) necessitates their 
exclusion early in the investigative scheme.
A further problem in the development of these guidelines 
has been the large number of investigative methods reported, 
particularly with regard to malabsorption. This reflects the 
failure of any single test to become established as the standard 
and, indeed, many of the available methods have not found a 
wide acceptance because of inadequate sensitivity, specificity 
or ease of use. Moreover, there is considerable variation in 
protocols and analytical methods between laboratories that 
leads to poor reproducibility of results.15 It is also unclear 
what place some of these tests (some of which were devised 
prior to the advent of endoscopy) hold in the current inves-
tigative scheme that incorporates access to small bowel and 
colonic histology. To circumvent this somewhat, we propose 
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in figure 1 an outline algorithm for the investigation of 
chronic diarrhoea based on clinical differential diagnosis. 
This will be used to guide the text in this document.
3 PrIMAry clInIcAl AssessMent
The initial assessment of patients with chronic diarrhoea can 
be mostly carried out in the primary care setting. The impor-
tance of careful history taking and examination cannot be 
overemphasised.
3.1 Initial presentation in primary care
In most countries where there is a split primary/secondary care 
system, the first consultation is with the primary care physi-
cian. Around 10% of all consultations in primary care are for 
gastroenterological problems, of which half are for lower gastro-
intestinal (GI) problems.16 Most of these are for self-limiting 
symptoms or for functional GI disorders and only a very small 
proportion comprise chronic or persistent diarrhoea. Based on 
the accepted definition of chronic diarrhoea being abnormal 
passage of ≥3 loose stools per day for more than 4 weeks and 
a rate of 3–5% per year,17 a primary care physician with an 
average list size of 1700 patients may have 50–85 such patients 
each year. Only a proportion of these will consult, with many 
managing with self- or pharmacy-based treatments, while others 
will be managed within primary care, often with antidiarrhoeals.
No data are available on the proportion referred to secondary 
care, but these are likely to be a small minority of the total 
number of people with chronic diarrhoea in the community. 
First-line investigations are normally performed within primary 
care and patients may be referred if their condition causes inter-
ference with normal activities or a compromise of quality of life 
sufficient to warrant further action. As with other conditions, 
many patients merely adapt their lives to their symptoms. No 
formal primary care referral guidelines or recommendations 
exist for patients with chronic diarrhoea, but the presence of 
normal first-line investigations with symptoms severe enough to 
impair quality of life and not responding to treatment constitutes 
a rationale for referral.
The impact of the symptoms of chronic diarrhoea and the 
differential diagnoses that need to be considered are clearly 
different in individual patients. A patient with recent change in 
bowel habit to include diarrhoea over 6 weeks is likely to need 
a different approach compared with another patient who has 
suffered from intermittent watery diarrhoea which has been 
present for over 5 years. Blood, stool (if an infectious aetiology 
or if an inflammatory component is suspected) and serological 
tests (for coeliac disease, hyperthyroidism and anaemia) should 
be performed in primary care as an initial assessment. Equally, 
if alarm features (such as unexplained change in bowel habit, 
persistent blood in the stool and unintentional weight loss) 
are detected, then referral for further investigations should be 
initiated.
3.2 History and examination: secondary care assessment
A detailed history is essential in the assessment of patients 
with chronic diarrhoea. This should attempt (a) to establish 
the likelihood that the symptoms are organic (as opposed to 
functional) based on presence of ‘alarm features’ as outlined 
above; (b) to distinguish malabsorptive from colonic/inflam-
matory forms of diarrhoea; and (c) to assess for specific causes 
of diarrhoea.
Symptoms suggestive of an organic disease include a history of 
diarrhoea of <3 months’ duration, predominantly nocturnal or 
continuous (as opposed to intermittent) diarrhoea and significant 
weight loss. The absence of these, in conjunction with positive 
symptoms such as those defined in the Rome IV criteria (improved 
clinical validation)18 and a normal physical examination, are 
suggestive of a functional bowel disturbance, but only with a spec-
ificity of approximately 52–74%.19 Unfortunately, these criteria 
do not reliably exclude inflammatory bowel disease (IBD), micro-
scopic colitis or bile acid diarrhoea, all of which are relatively 
common and treatable with specific approaches.20
Malabsorption is often accompanied by steatorrhoea and the 
passage of bulky malodorous pale stools. However, milder forms 
of malabsorption may not result in any reported stool abnor-
mality. Colonic, inflammatory or secretory forms of diarrhoea 
typically present with liquid loose stools with blood or mucous 
discharge.
Specific risk factors which increase the likelihood of organic 
diarrhoea or point to potential lines of investigation should be 
sought (see box 1). These include:
1. Family history: particularly of neoplastic, inflammatory 
bowel or coeliac disease.
2. Previous surgery: extensive resections of the ileum and right 
colon lead to diarrhoea due to lack of absorptive surface and 
hence fat and carbohydrate malabsorption, decreased transit 
time or changes in the bile acid pool including malabsorp-
tion.21 Bacterial overgrowth can often be a problem in this 
situation, particularly in bypass operations such as in gastric 
surgery and jejunoileal bypass procedures for morbid obesity. 
Shorter resections of the terminal ileum can lead to bile acid 
diarrhoea, which typically occurs after meals and usually 
responds to fasting and bile acid sequestrants (see sections 
5 and 6). 
Chronic diarrhoea may also occur in up to 10% patients 
after cholecystectomy through mechanisms that include 
increased gut transit, bile acid diarrhoea, and increased 
enterohepatic cycling of bile acids.22
3. Previous pancreatic disease.
4. Systemic disease: thyrotoxicosis and hypoparathyroid 
disease, diabetes mellitus,23 adrenal disease or systemic scle-
rosis may predispose to diarrhoea through various mecha-
nisms including endocrine effects, autonomic dysfunction, 
small bowel bacterial overgrowth or the use of concomitant 
drug therapy.
5. Alcohol: diarrhoea is common in alcohol abuse. Mechanisms 
include direct toxic effect on intestinal epithelium, rapid gut 
transit, decreased activity of intestinal disaccharidases and 
decreased pancreatic function.24
6. Diet: excessive intake of caffeine (eg, coffee, energy drinks), 
milk in patients with lactase deficiency, food additives (eg, 
sorbitol), fructose and other FODMAPs (fermentable oligo-, 
di-, mono-saccharides and polyols) should be sought (see 
section 5.3).
7. Drugs: up to 4% of cases of chronic diarrhoea may be due 
to medications (particularly magnesium supplements, anti-
hypertensives (eg, ACE inhibitors) and non-steroidal anti-in-
flammatory drugs, newer gliptins (dipeptidyl peptidase-4 
inhibitor), theophyllines, antibiotics, antiarrhythmics and 
antineoplastic agents).25
8. Recent overseas travel or other potential sources of infec-
tious gastrointestinal pathogens.
9. Recent antibiotic therapy and Clostridium difficile 
infection: many different tests are now available for the 
detection of C. difficile, but most clinical laboratories use 
a commercial enzyme immunoassay for C. difficile toxin 
(details in section 3.3.3).
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3.3 Initial investigations
3.3.1 Blood tests
Abnormal initial screening investigations such as a high eryth-
rocyte sedimentation rate, anaemia or low albumin have a high 
specificity for the presence of organic disease.26 The presence of 
iron deficiency is a sensitive indicator of small bowel enteropathy, 
particularly coeliac disease,27 but is obviously not a specific test. 
Guidelines regarding the approach to a patient with iron defi-
cient anaemia have previously been published.28 A basic screen 
for evidence of malabsorption should include full blood count, 
urea and electrolytes, liver function tests, vitamin B12, folate, 
calcium, ferritin, erythrocyte sedimentation rate and C reactive 
protein. Thyroid function tests should also be performed at this 
stage with a suppressed thyroid-stimulating hormone being the 
best predictor for hyperthyroidism.
3.3.2 Serological tests for coeliac disease
Coeliac disease is defined as a state of heightened immunological 
responsiveness to ingested gluten in genetically susceptible indi-
viduals.29 Epidemiological studies screening cohorts of healthy 
adult volunteers in the USA, UK and other European countries 
consistently report a prevalence of 0.5–1%.30–32 There is some 
evidence that the prevalence is increasing,33–35 and despite being 
a common global phenomenon, diagnosis is often delayed.36 37
The development of highly accurate serological tests and large 
epidemiological studies have contributed to our current under-
standing of coeliac disease. It is now recognised that the majority 
of patients may have more subtle presenting symptoms, adult 
presentations are more frequent than paediatric, and there is a 
‘pre-coeliac’ state.32 38 39
Recognition of the coeliac iceberg has improved understanding 
and detection of coeliac disease.37 The visible iceberg above the 
waterline depicts patients with typical GI symptoms such as diar-
rhoea and weight loss. The subsequent stratum just below the 
waterline represents patients considered to have atypical presen-
tations. They may have vague, non-specific GI symptoms such 
as bloating, or conditions associated with coeliac disease such as 
iron deficiency anaemia, osteoporosis and persistently abnormal 
liver function tests.40–42 Among certain groups the prevalence of 
coeliac disease will be higher (eg, type 1 diabetes, autoimmune 
thyroid disease or a first-degree relative with coeliac disease).43
Diarrhoea may be present in 43–85% of patients with newly 
diagnosed coeliac disease.40–42 44 45 Conversely, the prevalence 
of coeliac disease in patients referred to secondary care with 
chronic diarrhoea has been reported to range from 3% to 
10%.46 47 Given the delays in diagnosis for patients with unde-
tected coeliac disease and the fact that the tests are inexpensive43 
suggests that serological testing for coeliac disease in patients 
presenting with chronic diarrhoea is mandatory.
Endomysial antibody (EMA) and tissue transglutaminase 
antibody (TTG IgA) have a combined sensitivity and specificity 
of over 90% when used in combination in selected popula-
tions with a high prevalence of coeliac disease.48 49 However, 
when the prevalence of coeliac disease falls to 1%, as found 
in screening populations, the positive predictive value of these 
tests falls to around 80% or less.48 49 The sensitivity of the sero-
logical tests also falls well below 90% when histological grades 
less than Marsh 3 (villous atrophy) are considered.48–52 An IgA 
immunoglobulin level is also necessary as both EMA and TTG 
are IgA-based. In the presence of IgA deficiency, IgG EMA or 
IgG TTG should be performed.53 Finally, if the clinician is still 
suspicious, then a duodenal biopsy should be performed even in 
the presence of negative antibodies. Antibody-negative coeliac 
disease accounts for 6.4–7% of cases of patients presenting with 
coeliac disease.48 53
3.3.3 Immunodeficiency and infections
Immunodeficiency states complicate diagnosing the cause of diar-
rhoea. The first step is to identify the immunodeficiency. Beyond 
the common primary and haematological causes, clinicians 
should be aware that chronic diarrhoea is a common symptom in 
patients newly diagnosed with human immunodeficiency virus 
box 1 causes of chronic diarrhoea
common
 ► IBS-diarrhoea
 ► Bile acid diarrhoea
 ► Diet
 – FODMAP malabsorption
 – Lactase deficiency is highly prevalent in non-Caucasian 
ethnic groups
 – Artificial sweeteners (eg, sorbitol, xylol in chewing gum, 
soft drinks)
 – Caffeine (eg, coffee, coke, energy drinks)
 – Excess alcohol
 – Excess liquorice
 ► Colonic neoplasia
 ► Inflammatory bowel disease
 – Ulcerative colitis
 – Crohn’s disease
 – Microscopic colitis
 ► Coeliac disease
 ► Drugs
 – Antibiotics, in particular macrolides (eg, erythromycin)
 – Non-steroidal anti-inflammatory drugs
 – Magnesium-containing products
 – Hypoglycaemic agents (eg, metformin, gliptins)
 – Antineoplastic agents
 – Others (eg, furosemide, Olestra)
 ► Overflow diarrhoea
Infrequent
 ► Small bowel bacterial overgrowth
 ► Mesenteric ischaemia
 ► Lymphoma
 ► Surgical causes (eg, small bowel resections, faecal 
incontinence, internal fistulae)
 ► Chronic pancreatitis
 ► Radiation enteropathy
 ► Pancreatic carcinoma
 ► Hyperthyroidism
 ► Diabetes
 ► Giardiasis (and other chronic infection)
 ► Cystic fibrosis
rare
 ► Other small bowel enteropathies (eg, Whipple’s disease, 
tropical sprue, amyloid, intestinal lymphangiectasia)
 ► Hypoparathyroidism
 ► Addison’s disease
 ► Hormone secreting tumours (VIPoma, gastrinoma, carcinoid)
 ► Autonomic neuropathy
 ► Factitious diarrhoea
 ► Brainerd diarrhoea (possible infectious cause not identified)
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(HIV).54 Clinicians should be aware of HIV prevalence estimates 
in their region and test accordingly. Once an immunodeficiency 
has been identified, potential chronic infection with pathogens 
such as cryptosporidia or norovirus should be investigated.
Chronic diarrhoea due to infectious agents is unusual in 
the immunocompetent patient. Protozoan infections, such as 
giardiasis and amoebiasis, are most likely to result in chronic 
infections. Examination of three fresh stools for ova, cysts and 
parasites remains the mainstay of diagnosis and has a sensitivity 
of approximately 60–90% for detection of these organisms. If 
there is doubt about persisting Giardia infection, then the use of 
a stool ELISA (92% sensitivity and 98% specificity) has largely 
replaced the need for intestinal biopsies and wet (saline and iodine 
mount) preparations.55–58 Short course treatment with metroni-
dazole or tinidazole is effective.58 Serological testing (indirect 
haemagglutination test or ELISA) can be a useful adjunct in cases 
of amoebic liver abscess—more so in endemic areas.59 Clinicians 
should liaise with their local microbiology services to establish 
the diagnostic methods used, which may include transition to 
newer ELISA-based assays with greater sensitivity and specificity.
A notable exception is Clostridium difficile infection where 
diarrhoea can persist through failure of initial treatment or rapid 
relapse, which has consistently occurred in one in four patients 
in the placebo arms of recent clinical trials.60–62 Identification 
of a wide variation in testing approaches across Europe has led 
to recommendations for a standardised two-stage approach.63 
The first step identifies the presence of the organism with gluta-
mate dehydrogenase enzyme immunoassay (EIA), nucleic acid 
amplification testing or PCR. The second stage looks to demon-
strate active C. difficile toxin production through toxin EIA. 
Such a combination of a sensitive and then a specific test gives 
high negative and positive predictive values where tests agree. 
Where they do not, clinical judgement on the likelihood of infec-
tion will determine the need for treatment. The phenomenon 
of post-infectious IBS after C. difficile infection is recognised,64 
hence clinicians should be wary of excessive antimicrobial 
therapy on the basis of PCR alone, especially in the absence of 
clear evidence of toxin production.
4 cAncer or InflAMMAtIon
4.1 stool tests
The Bristol stool chart (see online supplementary material), 
which is validated, is a good tool to determine stool consistency 
and guide subsequent investigations.65 Stool weights are no 
longer used or recommended due their limited clinical value.
4.1.1 Faecal calprotectin
The inflammatory marker faecal calprotectin has recently been 
shown to be of value and the subject of a NICE Diagnostic 
Guideline (DG11).66 Calprotectin is released when inflamma-
tory processes occur due to the degranulation of neutrophil 
granulocytes. When the inflammation is within the intestinal 
tract, calprotectin is released into the intestinal lumen and is 
stable enough to be measured in faeces. NICE recommends the 
use of faecal calprotectin as an option in the differential diag-
nosis of IBS and IBD in adults with recent onset lower GI symp-
toms in whom cancer is not suspected. Thus patients with low 
calprotectin levels are unlikely to have any active inflammatory 
processes at the time of sample collection, making a diagnosis 
of IBD less likely.67 68 NICE uses the commonly quoted 50 μg/g 
faeces as the decision level above which IBD is more likely, 
although other causes of raised calprotectin include colorectal 
cancer, infectious gastroenteritis and non-steroidal anti-inflam-
matory drugs.69 This strategy should lead to a reduced level of 
secondary care referrals with associated lower cost and morbidity. 
There is some evidence that calprotectin levels >250 μg/g faeces 
suggest active inflammation correlating quite well with endo-
scopic inflammation.67 70 The issue of indeterminate levels still 
remains elusive, although one study that looked at the 12-month 
outcome of indeterminate faecal calprotectin levels (50–249 μg/g 
faeces) noted an 8% chance of developing IBD compared with 
1% in those with levels <50 μg/g faeces.71 For further details see 
online supplementary material.
4.1.2 Faecal occult blood test (FOBT)/faecal immunochemical 
technique (FIT)
The detection of excess blood in faeces has been used for many 
years in the diagnosis of colorectal cancer. There are two types 
of faecal occult blood test: the older gFOBT based on the oxidi-
sation of guaiac gum and the newer FIT for the detection of 
faecal haemoglobin, which uses an immunochemical technique 
to detect blood. Current European guidelines for colorectal 
cancer screening72 recommend the use of faecal haemoglobin 
and, although the UK still uses the older test, plans are well 
advanced to change to faecal haemoglobin in both Scotland and 
England in 2018 for screening. Emerging studies indicate that, 
in those with lower GI symptoms suggestive of colorectal cancer, 
FIT testing has a high negative predictive value (0.99) with the 
optimal cut-off between 7 and 10 μg/g faeces.73–75 With the 
appropriate quality assurance processes in place and good clin-
ical judgement, there is good evidence that using faecal haemo-
globin in symptomatic patients may be of benefit in reducing the 
burden of unnecessary colonoscopic examinations. For further 
details see online supplementary material.
4.2 endoscopic and histological assessment
In most patients with chronic diarrhoea, some form of endo-
scopic investigation will be necessary. In young patients (less 
than 40 years) reporting ‘diarrhoea’ but who have other typical 
symptoms of a functional bowel disorder and negative initial 
investigations, a diagnosis of IBS may be made in the primary 
care setting without recourse to further investigations.76 There 
recommendations
 ► We recommend an initial screening blood test (full blood 
count, ferritin, tissue transglutaminase/EMA and thyroid 
function test) as well as stool tests for inflammation (faecal 
calprotectin) should be undertaken in primary care (Grade of 
evidence level 3, Strength of recommendation strong).
 ► We recommend screening for coeliac disease using 
serological tests (tissue transglutaminase or EMA), which 
have a high sensitivity and specificity for the disease (Grade 
of evidence level 1, Strength of recommendation strong).
 ► If IgA deficient, we recommend either IgG EMA or IgG TTG 
should be performed (Grade of evidence level 2, Strength of 
recommendation strong).
 ► HIV infection should be excluded in those who are 
immunocompromised and present with chronic diarrhoea 
(Grade of evidence level 2, Strength of recommendation 
strong).
 ► We recommend combination testing for Clostridium difficile 
infection; confirmation of the presence of the organism by 
glutamate dehydrogenase enzyme immnunoassay or PCR and 
determining if these are toxin-producing (toxin EIA) (Grade of 
evidence level 2, Strength of recommendation strong).
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is some evidence that using anti-vinculin and anti-cytolethal 
distending toxin B antibodies may help with making a positive 
diagnosis of IBS.77 However, patients under 40 years without 
typical symptoms of functional bowel disorder and/or severe 
symptoms and documented diarrhoea (as previously defined) 
should have further evaluation (see section 3.2.3).
4.2.1 Colonoscopy
Screening colonoscopy in asymptomatic individuals detects 
colonic adenomas in 14.4–37.5% of cases,57 but few studies have 
addressed the frequency of neoplasia in symptomatic patients, 
and none has specifically addressed the prevalence of adenomas 
in patients undergoing colonoscopy for diarrhoea. Neugut and 
colleagues78 showed that, of 861 patients (with rectal bleeding), 
only 154 had a change in bowel habit of which 7% of these 
had colonic neoplasms. This would suggest that change in 
bowel habit is a poor guide to the prevalence of neoplasia unless 
advanced to the point of malignancy. Almost half had neoplasia 
proximal to the splenic flexure, indicating the need for full colo-
noscopy rather than flexible sigmoidoscopy in these patients.78 79
In addition to neoplasia, colonoscopy also has a diagnostic 
yield for other conditions ranging from 7% to 31%, with IBD 
and microscopic colitis being most commonly found. Hence both 
right- and left-sided colonic biopsies are necessary (see further 
details in section 5.2).80–83 Routine ileoscopy further adds to the 
value of colonoscopy. This led to a positive diagnosis in 18% of 
non-HIV patients who complained of diarrhoea.84 In patients 
in whom IBD is suspected, the value of ileoscopy and biopsy is 
further enhanced: 36% of patients with a normal colonoscopy 
and diarrhoea had terminal ileal disease.85 Although these results 
clearly reflect considerable referral bias, when taken together 
they suggest that, in chronic diarrhoea of uncertain origin, colo-
noscopy and ileoscopy with biopsy will lead to a diagnosis in 
approximately 15–20% of cases.
Colonoscopy is more sensitive than barium enema and, given 
this and the need to obtain histology to exclude colitis, barium 
studies of the colon are no longer indicated in chronic diar-
rhoea.86 87
4.2.2 Flexible sigmoidoscopy
Unprepared rigid sigmoidoscopy has long been used in the 
outpatient setting to quickly assess the rectum and stool. This 
remains an appropriate examination in those younger patients 
who on clinical grounds are believed to have a functional bowel 
disorder. Some authors conclude that, in this age group, most 
pathology occurs in the distal colon and is thus accessible with 
a flexible sigmoidoscope.8 80 In one study that examined the 
prevalence and anatomical distribution of colonic pathology 
in patients presenting with non-HIV-related chronic diarrhoea, 
15% of patients had colonic pathology.88 Some 99% of these 
diagnoses could have been made from biopsies of the distal 
colon using a flexible sigmoidoscope, the primary diagnoses 
being microscopic colitis, Crohn’s disease and ulcerative colitis. 
Other sources point more strongly to the need for full colonos-
copy in chronic diarrhoea of uncertain aetiology.57–62
4.2.3 Upper gastrointestinal endoscopy
There is little information on the diagnostic yield of upper GI 
endoscopy in patients whose diarrhoea is suspected to be due to 
malabsorption. This will clearly vary depending on the cohort of 
patients being investigated, referral criteria and degree of suspi-
cion for any given underlying diagnosis. Coeliac disease should 
be considered and investigated as per section 3.3.2.
4.3 small bowel imaging and visualisation for inflammation
4.3.1 Small bowel imaging for abnormality (eg, inflammatory bowel 
disease)
Traditionally the small bowel barium follow through (SBBFT) 
or barium enteroclysis was the standard means of assessing small 
bowel mucosa. However, barium examinations have both a 
low sensitivity and specificity in the detection of small bowel 
abnormalities.89 Ultrasonography (USS) may be used to assess 
the bowel, and the advantages include its non-invasiveness 
and availability. USS has been shown to have high sensitivity 
in the detection of terminal ileal pathology but its accuracy for 
disease proximal to the terminal ileum is lower compared with 
CT and MRI.90–92 The significant disadvantages of USS include 
the difficulty of viewing the GI tract in its entirety and high oper-
ator dependence.93–95
Cross-sectional modalities such as CT and MRI have emerged 
as the preferred imaging tests for evaluation of the small bowel. 
Specialised small bowel imaging procedures such as CT and 
MR enterography and enteroclysis have become preferred, as 
comparative studies have shown their superiority compared with 
SBBFT.93 95
The enterographic technique (CT or MR) is based on imaging 
after ingestion of a large amount of oral contrast over a set time 
period whereas the enteroclysis procedure requires nasojejunal 
intubation. The main disadvantage of an enteroclysis examina-
tion is the nasojejunal intubation, which is uncomfortable for 
patients leading to greater patient preference for enterography 
examinations.96 97
Recent validated studies have reported high accuracy of 
MR enterography examination for small bowel abnormalities 
compared with surgical findings.94 98–101 Further advances in 
MR technology with diffusion-weighted imaging (MR- DWI) 
are proving important for the diagnosis and assessment of bowel 
abnormalities.102 103 Although CT is also widely used in abdom-
inal imaging, its main disadvantage is the associated high radi-
ation burden. A recent meta-analysis has concluded that it is 
preferable to use a non-ionising modality such as USS or MRI 
in order to reduce radiation exposure.98 104 Several comparative 
studies also report that MRI has higher sensitivity than CT in the 
detection of small bowel diseases and neoplasms.94 96 98–100 103 105
Current evidence-based analysis indicates that either CT or 
MR enterography (depending on availability) should be the 
preferred initial test for the diagnosis of small intestinal abnor-
malities in patients with chronic diarrhoea. MRI is the preferred 
option as it does not entail high-dose radiation compared with 
CT imaging.101 105
4.3.2 Video capsule endoscopy
Capsule endoscopy has a role either as a means to distinguish 
small bowel abnormalities or to assess further the small bowel 
after a negative radiological (MR or CT) investigation. However, 
in some centres this may be viewed as a first-line investigation 
of the small bowel due to its non-invasive nature (patient tolera-
bility and acceptance) as well as increased diagnostic yield when 
compared by meta-analysis and systematic review against other 
small bowel investigations.106
When specifically considering coeliac disease, capsule endos-
copy is not recommended and patients should be encouraged to 
have a duodenal biopsy in order to obtain a histological diag-
nosis. For patients who are unable or unwilling to undergo a 
gastroscopy, a small bowel capsule may help to demonstrate 
villous atrophy in the presence of positive coeliac serology.
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4.3.3 Enteroscopy
Small bowel enteroscopy has been evaluated as a complementary 
investigation to SBBFT and capsule endoscopy, either as a means 
to distinguish small bowel abnormalities or to assess further 
the small bowel after a negative radiological investigation.107 
A key feature of enteroscopy studies in assessing inflammation 
or obscure bleeding is the consistently high false negative rate 
of prior upper and lower endoscopy, emphasising the need to 
ensure that adequate visualisation and biopsy of the duodenum 
and ileum have been achieved. Push enteroscopy may have some 
value to obtain jejunal biopsies in determining rare causes of 
diarrhoea—for example, cyclospora infections, sprue-related 
strongyloidosis or those with malabsorption/raised IgA TTG and 
non-diagnostic duodenal biopsies.108 Device-assisted enteroscopy 
(double balloon, single balloon or spiral) is complementary to 
capsule endoscopy and should be reserved for targeting lesions 
(and obtaining histology) or therapeutic intervention when 
abnormalities are identified by small bowel imaging or capsule 
endoscopy.106
5 coMMon DIsoDers
5.1 bile acid diarrhoea
Given that a third of patients labelled with diarrhoea-predomi-
nant IBS actually suffer from bile acid diarrhoea, this condition is 
more common than initially perceived with a significant impact 
on patients.109 110 Bile acids are required for the digestion of fat 
and are synthesised from cholesterol in the liver and excreted 
in the bile mainly in the form of glycine or taurine conjugates. 
This process is regulated through a negative feedback manner by 
nuclear farnesoid receptor as well as by fibroblast growth factor 
19 (FGF-19),111 112 a protein released from ileal enterocytes. Up 
to 95% of bile acids are reabsorbed through the enterohepatic 
circulation.
75SeHCAT testing (the standard radiolabelled test used to 
identify bile acid diarrhoea: tauroselcholic (Se) acid) was first 
described in 1982.113 114 A retention of 10–15% at 7 days is 
usually defined as mild bile acid loss, 5–10% as moderate and 
0–5% as severely abnormal. These values also predict response 
to therapy with bile acid sequestrants.115
The serum bile acid precursor 7α-hydroxy-4-cholesten-
3-one116 is an intermediary product in the synthesis of bile acids 
from cholesterol by the liver enzyme CYP7A1 and so provides a 
measure of bile acid synthesis. It has a negative predictive value of 
95% (positive predictive value of 74%) compared with SeHCAT, 
hence making it attractive as a screening test for excessive bile 
acid turnover.117 Levels above 47.1 ng/mL are indicative of bile 
acid diarrhoea.118 C4 requires a fasting sample, like FGF-19; 
both undergo diurnal and postprandial variation, with false posi-
tives also occurring in those with liver disease.119
Faecal bile acid measurement is another option with values 
>2300 µmol/48 hours indicative of bile acid diarrhoea.119 
However, as dietary fat intake and consequently bile acid 
levels are variable, it requires a 48-hour sample. Moreover, it 
is cumbersome and not yet commercially available in the UK. 
Additionally, other less invasive and economical tests such as 
urine testing for 2-propanol and acetone are currently being 
evaluated.120 A summary table of tests in bile acid diarrhoea are 
presented in these studies.121 122
Up to 30% of patients with diarrhoea-predominant IBS have 
evidence of bile acid diarrhoea as determined by SeHCAT 
testing.87 109 123 Compared with controls, IBS patients had 
lower SeHCAT values and higher C4 levels but similar FGF-19 
levels. More than 50% responded to bile acid sequestrants 
(colestipol).124 In addition to patients with ileal disease (eg, 
Crohn’s disease),125 bile acid diarrhoea has also been reported 
in patients following cholecystectomy and post-infectious diar-
rhoea.126 For those not responding to treatment, other additional 
causes should be sought (eg, bacterial overgrowth, pancreatic 
insufficiency or microscopic colitis),127 even if SeHCAT testing 
has been abnormal. Another under-recognised group are those 
with cancer who have received pelvic chemoradiotherapy 
as >50% have bile acid diarrhoea.128
The NICE DG7 diagnostic guidance report on SeHCAT in 
2013 and subsequent update in 2016 recognised the potential 
for patient and system benefits associated with SeHCAT inves-
tigations.129 One study suggests that the economic evaluation 
needs to be reconsidered as the impact of not making a positive 
recommendations
 ► We recommend use of faecal calprotectin in younger 
patients (under 40 years) with chronic diarrhoea in whom 
inflammation is suspected and not cancer (Grade of evidence 
level 1, Strength of recommendation strong).
 ► Cut-off of 50 μg/g faeces (assay-dependent) is recommended 
to distinguish functional bowel disorder from organic/
inflammatory bowel disease (Grade of evidence level 1, 
Strength of recommendation strong).
 ► In patients with typical symptoms of functional bowel 
disease, normal physical examination and normal screening 
blood and faecal tests (calprotectin), a positive diagnosis 
of IBS can be made (Grade of evidence level 2, Strength of 
recommendation strong).
 ► For those with lower gastrointestinal symptoms suspicious 
of colon cancer (without rectal bleeding), we suggest faecal 
immunological testing as a rule out test to guide need 
for referral or urgency of investigations either in primary 
or secondary care; (Grade of evidence level 2, Strength of 
recommendation weak)
 ► In patients with chronic diarrhoea, we recommend 
colonoscopy (with ileoscopy) and biopsy as the preferred 
investigation of the lower bowel (Grade of evidence level 1, 
Strength of recommendation strong).
 ► In younger patients (under 40 years) with a normal 
faecal calprotectin and in whom functional bowel disease 
is suspected, we recommend a flexible sigmoidoscopy 
with biopsy (Grade of evidence level 3, Strength of 
recommendation strong).
 ► We recommend either MR enterography or video capsule 
endoscopy (VCE) (depending on local availability) rather than 
CT as first-line investigation for diagnosing inflammation 
within the small bowel (Grade of evidence level 1, Strength 
of recommendation strong).
 ► We do not recommend VCE for the diagnosis of coeliac 
disease due to insufficient evidence (Grade of evidence level 
5, Strength of recommendation strong).
 ► Ultrasonography of the small bowel, while attractive due to 
its non-invasive nature and absence of radiation exposure, 
has a limited diagnostic role hence cannot be recommended 
routinely (unless other modalities are unavailable) (Grade of 
evidence level 4, Strength of recommendation strong).
 ► Enteroscopy (±device assisted) has limited diagnostic value 
for chronic diarrhoea and we recommend its role mainly 
for targeting predefined lesions (Grade of evidence level 4, 
Strength of recommendation strong).
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diagnosis leads to repeat (unnecessary) testing with additional 
cost to the NHS.130 More recently it has been shown that 
making a positive diagnosis of bile acid diarrhoea (in this study 
using SeHCAT) was economically beneficial as those who had 
negative SeHCAT tests underwent significantly more investiga-
tions (1.8x more), especially cross-sectional imaging (13x more 
likely), although those with a positive SeHCAT had more clinical 
appointments.131
A systematic review and meta-analysis comprising 36 studies 
and 5028 patients on bile acid diarrhoea biomarkers concluded 
that SeHCAT had the highest diagnostic yield to date (limited 
by study heterogeneity), with 25% previously diagnosed as 
having functional diarrhoea actually having primary bile acid 
diarrhoea.122
In a series of 264 patients where 53% had bile acid diarrhoea, 
44% failed to respond to cholestyramine alone. Half of these 
non-responders derived benefit from colesevelam (unlicensed 
but used with extended indication). Thus, lack of response to 
cholestyramine does not constitute exclusion of bile acid diar-
rhoea,132 hence therapeutic trials of bile acid sequestrants (chole-
styramine or colesevelam) are not recommended. Pooled data 
from 15 studies show a dose-response relationship between the 
severity of malabsorption and the effect of treatment with a bile 
acid sequestrant: clinical response to cholestyramine occurred 
in 96% of patients with <5% retention of SeHCAT, 80% 
at <10% retention and 70% at <15% retention.115
There are also logistic considerations for high throughput 
nuclear medicine departments as other concurrent studies 
may result in background radiation which could affect the 
7-day SeHCAT retention value; individual departmental proto-
cols should be in place to circumvent this issue.87
Bile acid diarrhoea should no longer be missed given the avail-
able option to test with either SeHCAT or serum C4. Other 
emerging serum and urine tests may soon be available. Once 
diagnosed, treatment is simple and effective.
5.2 Microscopic colitis
Collagenous colitis and lymphocytic colitis are two forms of 
microscopic colitis, both commonly presenting with chronic, 
non-bloody watery diarrhoea and with few or no endo-
scopic abnormalities.133 They were first described around 
1980.134 135Histological features are distinct from ulcerative 
colitis or Crohn’s disease and are not reliably detected on 
macroscopic examination at colonoscopy. Microscopic examina-
tion shows an increased number of intraepithelial and lamina 
propria lymphocytes (>20/100 cells) in both forms of micro-
scopic colitis, together with a thickened subepithelial collagen 
band (>10 µm) in collagenous colitis.136
These conditions have been the subject of several recent 
systematic reviews and meta-analyses and data from these have 
been used to inform the current guidance. The clinical presen-
tation, risk factors, pathology, disease course and response to 
treatment have been reviewed and compared for lymphocytic 
and collagenous colitis.137 138 The epidemiology and trends139 
and the diagnostic overlaps with IBS and functional GI disease 
have been reviewed.140 141 The American Gastroenterology Asso-
ciation has developed guidelines on the medical management of 
microscopic colitis.142 143
The overall prevalence of microscopic colitis ranges from 
about 50 to 200/100 000.143 Both forms are commoner in women 
(collagenous colitis 77%, lymphocytic colitis 68%) and the 
mean age at presentation is around 60.138 However, microscopic 
colitis can present in much younger patients with 25% of cases 
being under 45.137 The incidence of collagenous and lympho-
cytic colitis has been increasing in parallel, possibly related to 
greater awareness of the need to look for this diagnosis. There 
are overlapping histological features and the two forms cannot 
be distinguished on the basis of symptoms, although they may be 
less severe in lymphocytic compared with collagenous colitis.133 
Nocturnal diarrhoea and incontinence are frequently present.
In a meta-analysis of studies of patients meeting the criteria 
for diarrhoea-dominant IBS, the prevalence of microscopic 
colitis was 9.8% (95% CI 4.4% to 17.1%).140 Other reviews 
have also quoted a prevalence in patients being investigated for 
chronic diarrhoea of around 7.5–10%.133 142 Other functional 
bowel disorders, including constipation-predominant or mixed 
IBS, may also coexist with microscopic colitis. In patients with a 
diagnosis of microscopic colitis, about one-third have symptoms 
compatible with IBS, but this is a similar proportion to patients 
with other causes of chronic diarrhoea.141
Conditions associated with microscopic colitis include auto-
immune diseases such as rheumatic disease, thyroid disease and 
coeliac disease (in around 5–7%).133 137 142 Bile acid diarrhoea 
(diagnosed by SeHCAT testing) has been reported to be preva-
lent in both collagenous colitis (41%; 37–45%) and lymphocytic 
colitis (29%; 24–34%).138 Use of non-steroidal anti-inflamma-
tory drugs, proton pump inhibitors and sertraline is also high 
and withdrawal of these can be associated with improvement in 
symptoms.138
Diagnosis of microscopic colitis is made by histological exam-
ination of colonic mucosal biopsies. Multiple biopsies should 
be taken and examined to detect the histological changes of 
lymphocyte infiltration and a possible collagenous subepithelial 
band.136 It needs to be stressed that the colonoscopic macro-
scopic appearances may be essentially normal, but biopsies are 
still needed. Right-sided biopsies, taken at colonoscopy, have a 
greater yield than rectal biopsies, but most patients will have 
changes detectable in the distal colon and so can be diagnosed 
by biopsies taken at flexible sigmoidoscopy.82 83 There is no reli-
able biomarker for microscopic colitis, although a raised faecal 
calprotectin may be found,144 which will suggest the need for 
further colonoscopic assessment. A scoring system has been 
developed which has a good negative predictive value (97%) to 
exclude microscopic colitis.145 This may have a role in avoiding 
unnecessary colonoscopic biopsies in some patients.
Making the diagnosis of microscopic colitis in a patient 
with chronic diarrhoea is important as specific and effective 
treatment for the condition is now available. Budesonide, in 
controlled release preparations, has been shown to induce remis-
sion in active disease for both forms of microscopic colitis, and 
these trials have recently been reviewed.143 There is also good 
evidence for budesonide in the maintenance of remission in 
collagenous colitis.146 Up to 70% can relapse and require further 
treatment,147 but others can remain symptom-free. Other drugs 
have been used, including prednisolone, bile acid sequestrants in 
appropriate patients with demonstrated bile acid diarrhoea and, 
in steroid-refractory patients, immunosuppressives.142
5.3 Maldigestion of fructose-based carbohydrates and lactose 
and polyhydric alcohols
Maldigestion of fermentable oligo-, di-, mono-saccharides and 
polyols (FODMAPs) is a cause of diarrhoea in patients with IBS 
and other patient groups148 (eg, IBD in remission, enteral nutri-
tion). The mechanism by which these nutrients have effects on 
the GI tract has been described through detailed physiological 
and imaging studies.149–152
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Fructose is a hexose monosaccharide that is found in food 
on its own, as a disaccharide with glucose-forming sucrose and 
as longer chain polymers called fructans. Fructose is usually 
absorbed at the epithelium via the facilitative transporter GLUT5 
and the GLUT2 glucose-fructose co-transporter.153 The modern 
diet may contain high levels of isolated fructose or fructose in 
excess of glucose that exceed the absorption capacity of the small 
bowel (eg, soft drinks sweetened with corn syrup). Undigested 
fructose then passes into the colon and is fermented in the same 
manner as lactose in patients who are deficient in small intestinal 
lactase due to non-persistence of this enzyme expression into 
adult life.
Fructans are present in large concentrations in wheat, a staple 
of the diet for many populations (eg, bread, noodles). Fermenta-
tion of fructans by colonic bacteria is the cause of ‘wheat intol-
erance’ in many patients without coeliac disease.154 155 Similarly, 
sorbitol and other non-absorbed sugar alcohols (‘polyols’) used 
as artificial sweeteners pass unchanged into the colon and can 
induce diarrhoea if taken in large quantities (eg, diet drinks, 
chewing gum).
Interpretation of carbohydrate breath tests is particu-
larly contingent on the challenge dose used. Double-blind 
randomised controlled dietary challenge studies show a 
dose-response relationship between the intake of lactose, 
fructose and fructans with the likelihood of malabsorption 
(as assessed by an increase in breath hydrogen) and the devel-
opment of abdominal symptoms, including diarrhoea.150 The 
prevalence of primary lactase deficiency based on the pres-
ence of the 13 910 C/C genotype in the promoter region of 
the lactase enzyme gene is 2–15%, predominantly in Cauca-
sian populations in Northern Europe.156 A recent meta-analysis 
of epidemiological data reported that 68% (95% CI 64% to 
72%) of the world’s population are lactase-deficient,157 and 
this approaches 100% in the Han Chinese population.158 There 
is a high level of concordance between the presence of this 
genotype and lactose malabsorption.156 In contrast, there is no 
unique genotype linked with fructose or fructan malabsorption 
and a review of nine studies found that 25 g fructose may induce 
an increase in breath hydrogen in 40% of healthy subjects, but 
rarely induces symptoms.153 Prospective studies have shown 
that self-reported dietary intolerance is a poor predictor of 
objective test results158 159 or even response to dietary restric-
tion. Thus, breath testing after carbohydrate challenge could 
be useful if it identifies the cause of symptoms and predicts 
response to therapy. A positive lactose breath test fulfils these 
criteria,160 161 although avoidance of dairy products alone is 
rarely sufficient treatment in patients with IBS.161 162 No trials 
have directly addressed patients with isolated diarrhoea but, 
in diarrhoea-predominant IBS, two randomised controlled 
trials163 164 and one prospective study165 have found no rela-
tionship between the result of breath testing and response to 
dietary fructose reduction. At present, fructose breath testing 
cannot be said to inform diagnosis and treatment of fructose 
intolerance.
5.4 Post radiation diarrhoea
This is increasingly more common given that there is a three-
fold rise in cancer survivors in the last three decades. Many of 
the causes of chronic diarrhoea discussed in other sections of 
these guidelines are common in people who have been treated 
for GI and other cancers (eg, bile acid diarrhoea, pancreatic 
insufficiency). Specific guidance is now available as to how to 
investigate such patients, especially for the late effects of radia-
tion therapy.166
5.5 rapid intestinal transit
Many conditions associated with diarrhoea have been ascribed 
to abnormalities of gut motility and increased intestinal transit 
time. These include post-surgical states (eg, vagotomy), endo-
crine conditions (eg, hyperthyroidism), bile acid diarrhoea, 
autonomic neuropathy (eg, diabetes) and, most often, primary 
functional diarrhoea. Assessment of the contribution of disor-
dered motility and transit to diarrhoeal disease is hampered by 
the fact that (a) many of these conditions have multifactorial 
aetiologies; (b) available tests have limited ability to identify the 
cause of symptoms; and (c) wide individual variation in normal 
values precludes a definitive diagnosis in all except the most 
severe cases.
Detailed measurements of motility can be acquired by small 
intestinal or colonic manometry, ideally with high-resolution 
technology that clearly visualises propulsive and retrograde 
contractions that promote and inhibit transit.167 Pressure 
measurements are abnormal in the presence of obstruction and 
gross neuromuscular dysfunction, but findings in patients with 
severe symptoms do not correlate well with pathology on small 
bowel biopsy.168 In patients with chronic diarrhoea and IBS, the 
results are almost always normal and such invasive techniques 
are not well tolerated.169 170
recommendations
 ► If functional bowel disease or IBS-diarrhoea is suspected, we 
recommend that bile acid diarrhoea should be excluded with 
either 75SeHCAT testing or fasting serum C4 (7α hydroxy-
4-cholesten-3-one) levels. A test and treat approach is 
recommended as opposed to blind empirical therapy unless 
no diagnostic test is available (Grade of evidence level 1, 
Strength of recommendation strong).
 ► Patients with very low 75SeHCAT values are most likely to 
have a response to treatment with bile acid sequestrants. We 
recommend this is tried if the 75SeHCAT value is <15% or the 
fasting serum C4 is raised above defined laboratory values 
(Grade of evidence level 2, Strength of recommendation 
strong).
 ► We recommend colonic biopsies to exclude microscopic 
colitis. These should be at least from the left side (not rectal) 
and, as microscopic colitis can be patchy, right-side biopsies 
may improve diagnostic yield (Grade of evidence level 1, 
Strength of recommendation strong).
 ► Both glucose and lactulose hydrogen breath tests have poor 
sensitivity and specificity and are not recommended for the 
diagnosis of small bowel bacterial overgrowth (Grade of 
evidence level 2, Strength of recommendation strong).
 ► The utility of concurrent hydrogen and methane breath 
testing with measurements of orocaecal transit time 
could reduce a false positive diagnosis due to variability 
in intestinal transit, but has not been subject to definitive 
clinical study hence cannot be recommended (Grade of 
evidence level 4, Strength of recommendation strong).
 ► We recommend investigating for intestinal transit with 
manometry only if there is clinical suspicion and failure to 
respond to therapy (Grade of evidence level 4, Strength of 
recommendation strong).
 o
n
 22 M
ay 2018 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2017-315909 on 13 April 2018. Downloaded from 
12 Arasaradnam RP, et al. Gut 2018;0:1–20. doi:10.1136/gutjnl-2017-315909
Guidelines
Only patients who remain undiagnosed after extensive 
traditional investigation and failed medical therapy should be 
considered for manometry studies.171 In the future non-inva-
sive MRI  may find a role in the diagnosis of diarrhoeal condi-
tions. Recent studies have shown that this technique can provide 
comprehensive measurements of both motility and transit and 
can identify specific abnormalities in patients with diarrhoea-pre-
dominant IBS.172
6 tests for MAlAbsorPtIon
Malabsorption may occur as a result of a defective luminal 
environment such as inadequate bile acid or enzyme function, 
failure of epithelial transport due to mucosal disease or struc-
tural disorders (eg, fistula, surgical resection). Although there 
are generally coexisting deficiencies of fat, carbohydrate, 
protein, vitamins and minerals, the effects of one of these may 
predominate. Thus, pancreatic exocrine insufficiency is the most 
frequent cause of severe predominant steatorrhoea where faecal 
fat excretion exceeds 13 g/day (47 mmol/day).173 This is rare in 
mucosal or structural disease, although milder forms of steator-
rhoea are common. In comparison, carbohydrate malabsorption 
is predominantly associated with mucosal disease or dysfunc-
tion. Approaches to investigation involve either detection of 
the relevant compound in faeces or detection of an absorbed 
substance in the blood, urine or other tissues. A variation of the 
latter is the use of breath testing, which relies on the breakdown 
and bacterial fermentation of the test substance. These investi-
gations (stool fat, isotope breath or faecal tests, sugar and other 
permeability tests) were detailed by a previous version of these 
guidelines174 and will not be covered further here because, with 
the exception of hydrogen breath tests (see section 6.5.2), none 
have received significant support in publications since 2003 and 
they have not established themselves in clinical practice outside 
specialist centres.
6.1 fat malabsorption
Pancreatic exocrine insufficiency can lead to malabsorption (or 
more correctly maldigestion) and diarrhoea due to impairment 
of pancreatic enzyme and bicarbonate secretion. In adults, this 
is usually the result of chronic pancreatitis, pancreatic carci-
noma or pancreatic surgery. Maldigestion of fat can result in 
steatorrhoea and weight loss but may not be clinically apparent. 
Steatorrhoea can be caused by small bowel malabsorption and 
clinical assessment of steatorrhoea (eg, by stool inspection) is 
unreliable.175 Symptoms of pancreatic exocrine insufficiency 
usually develop 10–15 years after first symptoms of chronic 
pancreatitis and when secretion of lipase and other pancreatic 
enzymes is reduced to <10% of normal values. The diagnosis of 
advanced chronic pancreatitis in patients presenting with diar-
rhoea is often suggested by the clinical history and confirmed 
with imaging. A number of recent guidelines outline the current 
strategies for diagnosing chronic pancreatitis.176–179 There are 
international variations in practice depending on the availability 
of various modalities such as endoscopic ultrasound (EUS) and 
direct pancreatic function tests. However, there is a broad agree-
ment that invasive direct pancreatic function testing has become 
largely redundant in routine clinical practice, replaced by indi-
rect pancreatic function testing and imaging. It is also recognised 
that there is currently no ideal test to diagnose chronic pancre-
atitis in early/mild disease.
6.1.1 Faecal elastase
Three-day faecal fat estimation is laborious, unpleasant and is 
no longer performed in UK laboratories. Stool chymotrypsin 
assays have been replaced by faecal elastase because of its greater 
stability and the improved sensitivity of the test.
Human elastase-1 is an anionic protease belonging to the 
family of serine proteases along with other digestive enzymes 
such as chymotrypsin and trypsin. Its ability to degrade elastin 
is unique, but it is also stable in stool for up to a week at room 
temperature reaching concentrations 5–6 times higher than 
duodenal juice. This stool test has emerged as a preferred test of 
pancreatic function and has largely replaced invasive and indi-
rect pancreatic function tests in many centres. Normal values 
are 200–500 μg/g, with 100–200 μg/g in mild to moderate 
insufficiency and <100 μg/g in severe insufficiency. The test is 
unaffected by simultaneous enzyme therapy or diet and requires 
only a single 100 mg stool sample. Faecal elastase-1 has been 
well characterised as a sensitive biomarker for moderate to 
severe pancreatic insufficiency with sensitivities of 73–100% and 
specificities of 80–100%.180 181 However, faecal elastase is not 
useful in cases of mild pancreatic insufficiency with sensitivities 
of <60% and is not able to reliably distinguish pancreatic from 
non-pancreatic malabsorption. A comparison of faecal elastase 
with other non-invasive tests suggests superior sensitivity to the 
para-amino benzoic acid test182 and the pancreolauryl test.183 
The test should be used with care in patients with liquid stool 
and this can lead to false positive results (ie, low levels of faecal 
elastase due to dilution).
6.2 Pancreatic imaging
The progressive inflammatory change that occurs in chronic 
pancreatitis leads to significant changes in pancreatic structure. 
Focal segmental or diffuse destruction of the parenchyma occurs 
in the early stages while structuring, dilation of the duct and calci-
fication tend to occur late in the disease. There has been debate 
around the significance of the sometimes subtle changes found 
at EUS or endoscopic retrograde pancreatography (ERP) in the 
diagnosis of early chronic pancreatitis, particularly in patients 
presenting with abdominal pain. For more advanced pancreatic 
disease with significant morphological change, CT scanning has 
become the initial imaging of choice given the poor sensitivity of 
USS in this situation (approximately 60%)184 185 and in assessing 
for pancreatic malignancy. Its sensitivity in detecting early 
pancreatic changes is unknown, but it is significantly less than 
EUS or magnetic resonance cholangiopancreatography (MRCP)/
ERP. Newer non-invasive methods for diagnosing pancreatic 
cancer are beginning to emerge.186
MRCP with secretin (MRCP-S) appears to significantly 
increase the diagnostic yield in patients with asymptomatic 
hyperamylasaemia187and showed equivalent sensitivity to endo-
scopic retrograde cholangio-pancreatography (ERCP) in deter-
mining ductal changes in patients with idiopathic recurrent 
pancreatitis.188 The technique has been proposed as an alterna-
tive to direct pancreatic function tests, but issues of standardisa-
tion and interpretation remain to be resolved.189 190 Quantitative 
MRCP after secretin has also been correlated with faecal elastase 
and pancreolauryl testing191 192 and has been shown to correlate 
with histology.193 However, it is a specialised procedure and not 
recommended for initial diagnostic investigation for chronic 
pancreatitis.
EUS is able to detect mild parenchymal and ductal abnormalities 
not seen on CT. Comparison with ERCP in seven studies revealed 
sensitivity of 68–100% with specificity of 78–97%194 based on 
standard scoring of nine criteria. A study of 83 patients showed 
EUS to have an equivalent diagnostic accuracy for early and late 
stage chronic pancreatitis when compared with secretin direct 
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pancreatic function tests.195 196 Two studies comparing MRCP-S 
and EUS with ERCP have suggested a slightly higher sensitivity 
of EUS for changes suggestive of chronic pancreatitis,197 198 but 
it remains questionable whether some of the subtle findings at 
EUS have clinical relevance. Based on these and other studies, 
both EUS and MRCP-S would seem effective diagnostic tests for 
chronic pancreatitis, which are best used in a complementary 
fashion.
Local availability will inevitably dictate the choice of test, and 
both modalities would seem to be useful in assessing patients 
with early/mild forms of chronic pancreatitis, particularly if 
other approaches such as CT or pancreatic function tests are 
negative or equivocal. MRI with MRCP protocol is more sensi-
tive and accurate in the detection of chronic pancreatitis, as also 
recommended by the American Pancreatic Association.176
6.3 Invasive pancreatic function testing
Invasive tests of pancreatic function involving direct measure-
ment of pancreatic secretions (catheter aspiration of secretions 
after secretin, cholecystokinin stimulation or a standard test 
meal—the ‘Lundh test’) have historically been regarded as the 
gold standard for determining exocrine pancreatic function.199 200 
These tests are reported to correlate findings at ERCP,201 202 but 
some of these data are now more than three decades old with no 
recent re-evaluations of these earlier studies. Moreover, these 
tests are difficult to perform and compare as there is little stan-
dardisation. Although American guidelines continue to recom-
mend direct pancreatic function tests as part of the diagnostic 
investigation for chronic pancreatitis,176 there is no place in UK 
and European practice for these invasive tests.
6.4 non-invasive pancreatic function testing
These tests assess pancreatic enzymes or the consequences of 
maldigestion by measurement of stool, serum, urine or breath. 
The tests include fat, elastase and chymotrypsin measurement 
in stool, urine tests requiring detection of markers in urine or 
breath released from the gut and absorbed following digestion 
of synthetic substrate by pancreatic enzymes. All of these tests 
require significant loss of pancreatic function before becoming 
positive, with poor sensitivity and specificity in mild/early 
pancreatic disease.
6.4.1 Urine and breath tests
The two tests (NBTP and pancreolauryl) previously in use are 
now of largely historical interest as neither, to our knowledge, is 
in use in the UK due to their poor sensitivity and specificity.203
Equally, while European guidelines have recommended 
the use of the C13 mixed triglyceride breath test as an alter-
native to faecal elastase testing, it is not widely available with 
poor sensitivity in mild/moderate disease204 and therefore not 
recommended.
6.5 small bowel bacterial overgrowth (sbbo)
6.5.1 Introduction
The small bowel normally has little bacterial colonisation with 
concentrations in the proximal jejunum of less than 104 colony 
forming units (cfu)/mL in the normal healthy state compared 
with 109–1012 in the colon.
Few data exist on the prevalence of small bowel bacterial 
overgrowth (SBBO) in patients presenting with diarrhoea and/or 
malabsorption. However, patients with anatomical or functional 
reasons for abnormal orocaecal transit have been reported to 
be at increased risk. Such predisposing factors include diabetes, 
scleroderma, intestinal pseudo-obstruction, prior surgery (eg, 
terminal ileal resection), diverticulosis or strictures of the small 
bowel.205 Gastric surgery, in particular that involving a blind 
loop, is associated with a high prevalence of SBBO: up to 50% of 
patients with gastrojejunostomy and vagotomy compared with 
5% of those with vagotomy and pyloroplasty,206 although the 
clinical significance of this finding is unclear.207 Authors have 
also reported a high prevalence of SBBO in situations associ-
ated with achlorhydria such as old age or medical therapy with 
proton pump inhibitors.208 However, the clinical relevance of 
SBBO in this context has not been demonstrated.209 210
Part of the difficulty in establishing a confident diagnosis of 
SBBO is the lack of a standardised investigative tool. Culture of 
a small bowel aspirate is the most direct method of investiga-
tion of bacterial overgrowth and has been considered to be the 
gold standard for diagnosis of this condition by some authors.211 
The presence of >106 cfu/mL in either aerobic or anaerobic 
conditions is conventionally regarded as the criterion for a posi-
tive culture, although lower thresholds have been proposed. 
However, bacterial overgrowth, particularly due to coliforms 
and enterococci, may occur in apparently healthy individuals 
with no evidence of malabsorption,210 so the clinical relevance 
of such a positive result may be difficult to determine. Although 
malabsorptive syndromes have primarily been associated with 
anaerobic organisms, isolation and categorisation of bacterial 
anaerobes are not routinely performed in many laboratories. 
Furthermore, the lack of standardisation of bacterial counts, the 
possibility of sampling errors and the need for intubation make 
a simpler, less invasive investigation desirable.
6.5.2 Breath tests
Breath tests have been an attractive alternative to culture of 
small bowel aspirates for many years. However, the sensitivity 
and specificity of these tests are in general poor.
Hydrogen breath testing is based on the ability of some 
bacteria to ferment carbohydrates with an end product of 
hydrogen, which is not produced by mammalian cells. It was 
originally proposed that breath testing after a carbohydrate load 
resulted in a double peak due to metabolism by small bowel 
bacteria, followed by a more prolonged peak due to metabolism 
by colonic bacteria.212 The reproducibility of this double peak 
pattern has been challenged213 214 as the appearance of the initial 
peak is more likely to be due to fermentation by oropharyngeal 
flora or variation in orocaecal transit times and fermentation 
of carbohydrate in the caecum.215 In addition, a false negative 
result may occur in the 3–25% of individuals whose bacterial 
flora are not hydrogen producers.216 This may in part be due to 
variations in the particular species of bacteria involved in small 
bowel colonisation as, for example, none of Staphylococcus 
aureus, Enterococci spp, Serratia or Pseudomonas spp produce 
hydrogen.
Because of these problems, it is unsurprising that several studies 
have now shown the sensitivity and specificity of hydrogen 
breath tests to be low.211 217 Recently, Erdogan et al217 found that 
glucose breath testing had a sensitivity less than 50% compared 
with duodenal aspirate, regardless of whether or not methane 
measurement was added to hydrogen. Both the positive and 
negative predictive values for breath testing were less than 70%. 
Corazza and colleagues211 found sensitivities of 62% and 68% 
for glucose and lactulose-hydrogen breath tests, respectively. 
These studies support the poor results with the 10 g lactulose test 
reported by Riordan and colleagues,218 with a sensitivity of only 
17% and a specificity of 70%. The authors used scintigraphy to 
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aid interpretation of the breath test, and this increased sensitivity 
to 39% and specificity to 100%.219 220
This illustrates a key underlying flaw of breath testing in 
isolation: that transit time is assumed rather than measured. 
The result of this assumption is that fast orocaecal transit can 
confound interpretation of an early hydrogen peak, a circum-
stance that is more likely after intestinal resection. This issue 
has been demonstrated in high-quality physiological and clinical 
studies with both lactulose and glucose.214 219 220
The methodological problems and performance of hydrogen 
breath testing mean that it may add little when SBBO is 
suspected. A positive test will reinforce the clinician’s prior view 
that the cause may be SBBO; a negative test will not exclude the 
diagnosis as a possibility. It is not clear that such an intermediate 
investigative step is necessary or of value. It would be reasonable 
to test for SBBO in patients with diarrhoea and a low to moderate 
pretest probability of SBBO. However, where the pretest proba-
bility is high—for example, in those with anatomical abnormali-
ties such as dilation, diverticulosis, prior small bowel surgery or 
pseudo-obstruction—the most practical approach would be to 
proceed straight to an empirical antibiotic trial.
Strengthening facilities for microbiological analysis of gut 
flora after endoscopic sampling is likely to be a more productive 
focus for service development. Culture of unwashed mucosal 
biopsies may facilitate collection of microbiological samples 
rather than by using jejunal aspirates.221 In its absence, most 
units will remain reliant on assessing the effect of an empirical 
trial of antibiotics.222
7 surGIcAl/structurAl cAuses of DIArrHoeA
There is significant overlap of the type of patient referred to 
a surgeon rather than a gastroenterologist and many of the 
assessment and investigation recommendations are relevant. 
Often patients are directed towards surgeons through the urgent 
pathway where there is a need to exclude organic disease. In 
respect of these patients, investigations should follow the same 
assessment and investigation pathway as detailed above and in 
the NICE guidance CG131 (https://www. nice. org. uk/ guidance/ 
cg131). There is a tendency—once organic disease, particularly 
neoplasia and IBD, have been excluded—for the surgeon to 
either reassure the patient and discharge or refer on to a gastro-
enterologist. This may be appropriate but it is prudent for the 
surgeon to bear in mind other potential organic aetiologies. For 
instance, unrecognised cases of coeliac disease are sometimes 
seen in colorectal clinics. Patients present with vague GI symp-
toms, iron deficiency anaemia or chronic diarrhoea and are often 
falsely diagnosed as diarrhoea-predominant IBS.223
7.1 faecal incontinence
Some groups of patients are directed towards surgeons because 
diarrhoea is not the primary patient-perceived symptom. 
A typical example is faecal incontinence. Such patients may 
well have a compromised sphincter complex but fail to 
maintain continence because of the underlying diarrhoea. 
Although an important risk factor for incontinence along 
with age, obstetric trauma, pelvic surgery, obesity and other 
medical conditions such as diabetes and stroke, it may not be 
recognised and investigated appropriately. Again, NICE gives 
guidance as to appropriate management with baseline assess-
ment aimed at addressing underlying conditions such as poten-
tially treatable causes of diarrhoea (https://www. nice. org. uk/ 
guidance/ cg49). An associated group who may complain of 
both faecal incontinence and diarrhoea are those with severe 
faecal loading where the diarrhoea is essentially overflow. 
Typical patients tend to be those with cognitive or behavioural 
issues, have learning difficulties, or those with neurological 
or spinal disease. A focused baseline assessment should there-
fore include an anorectal examination which will identify 
impaction and, for instance, rectal prolapse. Plain radiography 
or radio-opaque marker studies have been used but there is 
poor correlation between the two.224 Specialist investigations 
include anorectal manometry and endoanal ultrasound, but 
there are no accepted standards for performing these specialist 
tests. The evidence behind their use is limited to the fact that 
they are better than simple clinical assessment in deciding 
surgical management. Therefore, they should only be insti-
gated once conservative measures for faecal incontinence have 
been exhausted and surgical intervention is contemplated.
7.2 Post-surgical diarrhoea
There is a third group of ‘surgical’ patients with diarrhoea. These 
are the patients who have developed diarrhoea as a result of 
surgical intervention. The underlying aetiology of the diarrhoea 
may be attributed to pyloric dysfunction, bile salt malabsorption, 
bacterial overgrowth or gut bypass reducing absorptive capacity.
Upper GI surgery may result in damage or division of the 
vagus nerve accompanied in part by reduction in capacity of the 
stomach in the case of gastric resection. Rapid gastric emptying 
may result in osmotic diarrhoea and associated symptoms of 
‘dumping’ syndrome. Surgery can also provide an ideal envi-
ronment for bacterial colonisation and overgrowth leading to 
chronic diarrhoea. GI tract surgeries that create a blind loop (eg, 
a Billroth II procedure or a Roux-en-Y anastomosis) may predis-
pose to stasis and overgrowth due to abnormal motility and 
ineffective clearance of retained food and secretions.225 In addi-
tion, those who have undergone jejunoileal bypass, an end-to-
side enteroenteric anastomosis or the creation of a Koch distal 
ileal pouch are at risk. In the same way, small bowel strictures 
may lead to bacterial stasis and overgrowth. These may occur 
recommendations
 ► We recommend faecal elastase testing as the preferred 
non-invasive test for pancreatic function (Grade of evidence 
level 1, Strength of recommendation strong).
 ► MRI (with MRCP protocol) is the recommended investigation 
of choice for diagnosing chronic pancreatitis. If unavailable, 
CT would be the next modality of choice (Grade of evidence 
level 2, Strength of recommendation strong).
 ► In cases where pancreatic insufficiency is strongly suspected 
but initial screening tests are negative, we suggest further 
imaging with either EUS or MRCP with secretin (if available) 
(Grade of evidence level 3, Strength of recommendation 
weak).
 ► We suggest culture of small bowel aspirates as it is the most 
sensitive test for small bowel bacterial overgrowth (SBBO), 
but methods are poorly standardised and positive results may 
not reflect clinically significant SBBO (Grade of evidence level 
2, Strength of recommendation weak).
 ► In the absence of an optimal test to confirm the presence 
of bacterial overgrowth and in those with a high test 
probability of SBBO, we recommend an empirical trial of 
antibiotics; the value of this approach has not been subject 
to definitive study (Grade of evidence level 3, Strength of 
recommendation strong).
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after surgery but can also be seen after radiotherapy, in Crohn’s 
disease and secondary to some medications.226
Small and large bowel resection clearly reduces absorptive 
capacity. At the extreme, this results in short bowel syndrome 
characterised clinically by chronic diarrhoea, dehydration, elec-
trolyte abnormalities and malnutrition. The severity and manage-
ment depend on the site and extent of the intestinal resection, 
whether there is disease in the residual bowel and the degree 
of adaptation of the remaining bowel. However, even a simple 
limited right hemicolectomy may result in diarrhoea as a result 
of loss of the ileocaecal valve and resorptive capacity of the right 
colon. This increases the risk of developing bacterial overgrowth 
because of retrograde movement of bacteria from the colon into 
the small intestine. This has been clearly demonstrated in one 
trial of patients with Crohn's disease which showed that resec-
tion of the ileocaecal valve almost doubled the prevalence of 
bacterial overgrowth.227
7.3 fistulae
The common theme in many of these surgical conditions is struc-
tural change. However, structural change may not necessarily 
be surgically induced. Disease processes can also predispose to 
gut bypass, bile acid diarrhoea and bacterial overgrowth. Fistula 
formation, such as commonly seen in Crohn’s disease, is one 
example of gut bypass. Cholecystoenteric fistulae are a poten-
tial cause of bile acid diarrhoea, particularly if the fistula is to 
the colon.228 Small bowel diverticula which occur in approxi-
mately 1–6% of the population may harbour bacteria and result 
in bacterial overgrowth.229
7.4 Investigations
In terms of investigation, clearly surgically-induced structural 
change may be obvious from the history. A digital rectal exam-
ination is essential. It allows clinical assessment of the sphincter 
complex and will exclude faecal impaction as well as low 
anorectal lesions. Further investigations, if required, to examine 
for structural change are mainly radiological; CT scanning and 
contrast studies will identify the structural changes.
8 rAre cAuses
8.1 neuroendocrine tumours
Hormone secreting tumours arising from gastroenteropancreatic 
tissue are rare causes of diarrhoea. The prevalence of functional 
pancreatic endocrine tumours is approximately 10 per million 
population, the incidence ranging from 1/106 cases per year in 
the case of gastrinomas to fewer than 1/107 cases per year for 
vasoactive intestinal peptide (VIP)omas and glucagonomas.230 
Even this incidence value is likely to be an overestimate. Diar-
rhoea occurs as part of a symptom complex varying according 
to the tumour type (eg, 100% cases in VIPoma, approximately 
65% in gastrinoma). Although diarrhoea has been reported at 
a prevalence of 15% in glucagonoma, this again is probably an 
overestimate. A wide variety of other symptoms may accompany 
hypersecretion of these hormones and detailed discussion is 
available elsewhere.231
Confirmation of the diagnosis in each case requires demon-
stration of an elevated serum hormone concentration. A VIP 
secreting tumour may be suspected in the context of large 
volumes of secretory diarrhoea (>1 litre/day), dehydration and 
hypokalaemia. Normal values for circulating VIP are less than 
170 pg/mL, while mean VIP serum concentrations in patients 
with functioning tumours range from 675 to 965 pg/mL.232As 
serum levels fluctuate, the assay should be performed during an 
episode of diarrhoea. Similarly, serum gastrin levels in patients 
with gastrinomas are considerably higher than the normal range 
of 150 pg/mL, with average values of approximately 1000 pg/
mL. However, comparable values can be found in patients with 
pernicious anaemia, other types of atrophic gastritis or potent 
acid suppressant therapy.233 Raised levels, although not to the 
same degree, also occur in other conditions such as diabetes 
mellitus, renal insufficiency and rheumatoid arthritis.
Diarrhoea is often a prominent feature (occuring in up to 
50% of cases234) in carcinoid syndrome, which accounts for 
20% of midgut neuroendocrine tumours.235 This almost always 
occurs in the context of hepatic metastases, even if the primary 
site remains undefined. The clinical diagnosis of ‘malignant 
disease’ is usually evident. A raised 24-hour urinary 5-hydroxy-
indoleacetic acid (above the local reference laboratory value) has 
a high sensitivity and specificity (88%)236 for the condition and 
correlates with tumour bulk, bioactive product secretion and, 
frequently, with the severity of symptoms.237 However, this is 
subject to patients adhering to dietary restrictions and often a 
3-day dietary intake should accompany the sample so the labo-
ratory can assess for any dietary interference (eg, serotonin-rich 
food such as bananas).235
8.2 factitious diarrhoea
Factitious diarrhoea caused by laxative abuse or the spurious 
adding of water or urine to stool specimens has been recognised 
as a relatively common cause of reported chronic diarrhoeal 
symptoms in Western populations. The likelihood of this diag-
nosis increases as more numerous and repeated investigations 
reveal negative results. Thus, although only 4% of patients 
visiting district gastroenterology clinics had factitious diarrhoea, 
this value increased to 20% of those evaluated at tertiary referral 
centres, which made it the most common cause of diarrhoea of 
previously undetermined origin.15 Similarly, a survey of patients 
who had undergone extensive evaluation revealed 33% who 
were found to be taking laxatives or diuretics; 22% had undi-
agnosed colitis (ulcerative or microscopic colitis), 7% had faecal 
incontinence and 7% had other organic disorders.26
Repeated analysis of stool and urine is wise, as patients may 
ingest laxatives intermittently. Alkalinisation assays, although 
simple to use (phenolphthalein, some anthraquinones and 
rhubarb turn the stool red, bisacodyl turns it purple-blue), are 
not of sufficient sensitivity and should be abandoned. A screen 
for ‘laxative abuse’ should include the detection of anthraqui-
nones, bisacodyl and phenolphthalein in urine and magnesium 
and phosphate in stool, and should be carried out in a specialist 
recommendations
 ► Faecal impaction with overflow diarrhoea should be 
considered especially in the elderly. We recommend clinical 
judgement rather than marker studies to confirm this (Grade 
of evidence level 4, Strength of recommendation strong).
 ► For patients with persistent faecal incontinence we 
recommend anorectal manometry and endoanal 
ultrasonography once conservative measures have 
been exhausted (Grade of evidence level 3, Strength of 
recommendation strong).
 ► If a fistula is suspected, cross-sectional imaging with contrast 
is recommended (Grade of evidence level 3, Strength of 
recommendation strong).
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laboratory. Laboratories in the UK performing these tests should 
participate in the UK External Quality Assessment scheme for 
the detection of laxatives. 
9 suMMAry AnD conclusIons
Establishing a clear definition of diarrhoea based on history 
alone can prove difficult, and this tends to lead to overinvestiga-
tion of functional diarrhoea including IBS. Serological testing for 
coeliac disease, the most common small bowel enteropathy in 
Caucasian populations, should be performed early in the course 
of investigations. The initial assessment should direct the clini-
cian to determine whether further investigation is necessary and, 
if so, whether the focus should be on colonic, small bowel or 
pancreatic disease. This analysis could reasonably be performed 
in the primary care setting.
Most chronic diarrhoea is due to colonic abnormalities. 
Colonic investigations should be age stratified, in keeping with 
the risk of neoplasia and inflammation, and the high prevalence 
of bile acid diarrhoea estimated to be similar to coealic disease 
should be recognised and investigated. After appropriate normal 
investigations, those with persistent diarrhoea are likely to be 
self-limiting ‘idiopathic’ diarrhoea or undiagnosed factitious 
diarrhoea.26 238 Since the overall prognosis appears to be good 
in this group, including those that self-report and self-remedy,239 
further investigation in this group is not warranted and symp-
tomatic treatment could be instituted.
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